Clene Inc.: management transactions · United States · SEC (Form 4)

About Clene Inc.

Clene Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq (CLNN) in the United States, with headquarters in Salt Lake City, Utah, and manufacturing plus R&D operations in Maryland. The company was founded in 2013 and has built its identity around a proprietary nanomedicine platform designed to restore neuronal health and function. For investors, Clene sits squarely in the neurodegenerative-disease innovation space, where the investment case is driven by clinical execution, regulatory progress, and financing capacity rather than near-term commercial scale. ([invest.clene.com](https://invest.clene.com/)) Clene’s lead asset is CNM-Au8®, an oral suspension of gold nanocrystals intended to improve cellular energy production and utilization by targeting mitochondrial function, the NAD pathway, and oxidative stress. The company is developing CNM-Au8 across several neurological indications, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease. In other words, Clene remains a development-stage biotech: its value proposition depends primarily on clinical data readouts, regulatory discussions, and the ability to raise capital, not on a mature product portfolio. ([invest.clene.com](https://invest.clene.com/news-releases/news-release-details/clene-reports-full-year-2025-financial-results-and-recent)) From a competitive standpoint, Clene is a niche player in a highly specialized segment of the biotech market. Its differentiation rests on a novel mechanism, a neuroprotective thesis, and the possibility of addressing diseases with substantial unmet medical need. That said, the company’s commercial position remains early and speculative, which is typical for small-cap U.S. biotech firms focused on central nervous system disorders. Management emphasizes scientific credibility and regulatory readiness, supported by executives with pharmaceutical, commercialization, and development experience. ([clene.com](https://clene.com/about/)) Recent developments have been particularly important. In March 2026, Clene said an in-person FDA Type C meeting was scheduled for the first quarter of 2026 to review the latest CNM-Au8 data, with the company targeting an ALS NDA submission under the accelerated approval pathway in the second quarter of 2026 if the interaction is positive. The company also disclosed an oversubscribed registered direct offering of more than $28 million in January 2026, followed by a $7 million underwritten offering announced in May 2026. Taken together, these updates show both progress toward a potential regulatory filing and the continuing importance of equity financing to sustain operations. For international investors, Clene is best viewed as a high-risk, catalyst-driven Nasdaq biotech in the United States, with upside tied to FDA milestones and clinical validation. ([invest.clene.com](https://invest.clene.com/news-releases/news-release-details/clene-reports-full-year-2025-financial-results-and-recent))